DPP4 and Hypoglycemia: In clinical practice guidelines, dipeptidyl peptidase-4 (DPP-4) inhibitors are primarily recommended for second-line treatment as an alternative to other antidiabetics, especially when aiming to reduce risk for hypoglycaemia.8,9 Likewise, guidelines for older adults assume that DPP-4 inhibitors may reduce the risk for hypoglycaemia and therefore are considered as a preferred treatment in older patients.10